REFERENCES
1. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039.
3. Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17:515-32.
4. Arnaud L, Parodis I, Devilliers H, Chasset F. Clinical trial outcomes for SLE: what we have and what we need. Lupus Sci Med. 2024;11:e001114.
5. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75:1615-21.
6. van Vollenhoven RF, Bertsias G, Doria A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8:e000538.
7. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83:15-29.
8. Nakayamada S, Iwata S, Tanaka Y. Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus. Int J Rheum Dis. 2015;18:208-18.
9. Dörner T, Lipsky PE. The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2024;20:770-82.
10. Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus. 2003;12:783-7.
11. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673-7.
12. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470-5.
13. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222-33.
14. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215-26.
15. Fanouriakis A, Kostopoulou M, Boumpas DT, et al. 2019 update of the joint european league against rheumatism and european renal association-european dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79:713-23.
16. Sammaritano LR, Askanase A, Mustafa RA, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of Lupus Nephritis. Arthritis Rheumatol. 2025;77:1115-35.
17. Iwata S, Saito K, Tokunaga M, Tanaka Y. B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE. Ann Rheum Dis. 2012;71:1749-50.
18. Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81:100-7.
19. Chu SY, Vostiar I, Karki S, et al. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol. 2008;45:3926-33.
20. Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;2:CD010668.
21. Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117-28.
22. Furie R, Rovin BH, Houssiau F, et al. Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study. Clin J Am Soc Nephrol. 2022;17:1620-30.
23. Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101:403-13.
24. Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 2013;65:2672-9.
25. Shipa M, Santos LR, Nguyen DX, et al. Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial. Lancet Rheumatol. 2023;5:e24-35.
26. Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 2021;73:121-31.
27. Agmon-Levin N, Ignatenko S, Gordienko A, et al. OP0089|phase 2 safety and efficacy of subcutaneous (S.C.) dose ianalumab (VAY736; anti-BAFFR mAb) administered every 4 weeks up to 48 weeks in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis. 2024;83:140-2.
28. Dörner T, Santos Da Costa A, Oliver S, et al. POS0540 reduction of B cell subsets, autoantibodies and disease-relevant pathways in ianalumab treated patients with systemic lupus erythematosus: findings from a phase 2 clinical trial. Ann Rheum Dis. 2024;83:956-7.
29. Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74:2006-15.
30. Wu D, Li J, Xu D, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83:475-87.
31. Evans LS, Lewis KE, DeMonte D, et al. Povetacicept, an enhanced dual APRIL/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases. Arthritis Rheumatol. 2023;75:1187-202.
32. Nakayamada S, Takahashi H, Kanno Y, O'Shea JJ. Helper T cell diversity and plasticity. Curr Opin Immunol. 2012;24:297-302.
33. Ramanujam M, Steffgen J, Visvanathan S, Mohan C, Fine JS, Putterman C. Phoenix from the flames: rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis. Autoimmun Rev. 2020;19:102668.
34. Furie RA, Bruce IN, Dörner T, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology. 2021;60:5397-407.
35. Cutcutache I, Powlesland AS, Skelton A, et al. POS0334 dapirolizumab pegol impacts important immunologic pathways in systemic lupus erythematosus: pharmacodynamic analysis of B cell and type I interferon pathways from a phase 2B trial. Ann Rheum Dis. 2024;83:265.
36. Clowse M, Isenberg D, Merrill J, et al. Dapirolizumab pegol demonstrated significant improvement in systemic lupus erythematosus disease activity: efficacy and safety results of a phase 3 trial [abstract]; 2024. Available from: https://acrabstracts.org/abstract/dapirolizumab-pegol-demonstrated-significant-improvement-in-systemic-lupus-erythematosus-disease-activity-efficacy-and-safety-results-of-a-phase-3-trial/ [Last accessed on 26 Feb 2026].
37. Karnell JL, Albulescu M, Drabic S, et al. A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity. Sci Transl Med. 2019;11:eaar6584.
38. Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019;129:1359-71.
39. Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus. N Engl J Med. 2022;387:894-904.
40. Werth VP, Furie RA, Romero-Diaz J, et al. Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N Engl J Med. 2022;387:321-31.
41. Ostendorf L, Burns M, Durek P, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383:1149-55.
42. Roccatello D, Fenoglio R, Caniggia I, et al. Daratumumab monotherapy for refractory lupus nephritis. Nat Med. 2023;29:2041-7.
43. Manzi S, Bruce IN, Morand EF, et al. Efficacy and safety of subcutaneous anifrolumab in systemic lupus erythematosus: a randomized, phase 3 study. Arthritis Rheumatol. 2025.
44. Alduraibi F, Fatima H, Hamilton JA, Chatham WW, Hsu HC, Mountz JD. Lupus nephritis correlates with B cell interferon-β, anti-Smith, and anti-DNA: a retrospective study. Arthritis Res Ther. 2022;24:87.
45. Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133-45.
46. Kubo S, Yamaoka K, Kondo M, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014;73:2192-8.
47. Merrill JT, Tanaka Y, D'Cruz D, et al. Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial. Arthritis Rheumatol. 2024;76:1518-29.
48. Merrill J, Saxena A, Aringer M, et al. Efficacy and safety of ABBV-599 (elsubrutinib and upadacitinib combination) and upadacitinib monotherapy for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study; 2024. Available from: https://acrabstracts.org/abstract/efficacy-and-safety-of-abbv-599-elsubrutinib-and-upadacitinib-combination-and-upadacitinib-monotherapy-for-the-treatment-of-systemic-lupus-erythematosus-results-through-104-weeks-in-a-long-term-ext/ [Last accessed on 26 Feb 2026].
49. Hasni SA, Gupta S, Davis M, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12:3391.
50. Dörner T, Tanaka Y, Dow ER, et al. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Ann Rheum Dis. 2022;81:1267-72.
51. Werth VP, Fleischmann R, Robern M, et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology. 2022;61:2413-23.
52. Morand E, Merola JF, Tanaka Y, Gladman D, Fleischmann R. TYK2: an emerging therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2024;20:232-40.
53. Satoh-Kanda Y, Nakayamada S, Kubo S, et al. Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus. RMD Open. 2024;10:e003991.
54. Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023;75:242-52.
55. Su LC, Xu WD, Huang AF. IRAK family in inflammatory autoimmune diseases. Autoimmun Rev. 2020;19:102461.
56. Isenberg D, Furie R, Jones NS, et al. Efficacy, safety, and pharmacodynamic effects of the bruton's tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021;73:1835-46.
57. Li R, Zhu X, Liu S, et al. LB0005 orelabrutinib, an irreversible inhibitor of bruton's tyrosine kinase (BTK), for the treatment of systemic lupus erythematosus (SLE): RESULTS of a randomized, double-blind, placebo-controlled, phase IB/IIA dose-finding study. Ann Rheum Dis. 2022;81:210.
58. Fillatreau S, Manfroi B, Dörner T. Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17:98-108.
59. Morand EF, Bender A, Deshpande A, et al. AB0444 enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (willow). Ann Rheum Dis. 2022;81:1350-1.
60. Pearson D, Morand E, Wenzel J, et al. Randomized, placebo-controlled phase II study of enpatoran, a small molecule toll-like receptor 7/8 inhibitor, in cutaneous lupus erythematosus: results from cohort A. J Rheumatol. 2025;52 Suppl 1:1-269.
61. Morand E, Dall'Era M, Furie RA, et al. LB0004 randomised, placebo-controlled phase II study of oral enpatoran, a first-in-class toll-like receptor 7/8 inhibitor, in systemic lupus erythematosus. Ann Rheum Dis. 2025;84:316-7.
62. Tanaka Y, Kumanogoh A, Atsumi T, et al. Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus. RMD Open. 2024;10:e004701.
63. Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397:2070-80.
64. Abdalhadi HM, Chatham WW, Alduraibi FK. CAR-T-cell therapy for systemic lupus erythematosus: a comprehensive overview. Int J Mol Sci. 2024;25:10511.
65. Mougiakakos D, Krönke G, Völkl S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385:567-9.
66. Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024;390:687-700.
67. Kollert F, Robertson S, Schuler F, et al. Characterization of RO7507062, a CD19-targeting T-cell bispecific antibody (CD19TCB), and design of its ongoing phase 1 trial in systemic lupus erythematosus; 2024. Available from: https://acrabstracts.org/abstract/characterization-of-ro7507062-a-cd19-targeting-t-cell-bispecific-antibody-cd19tcb-and-design-of-its-ongoing-phase-1-trial-in-systemic-lupus-erythematosus/ [Last accessed on 26 Feb 2026].
68. Domingo-Gonzalez R, Baribaud I, Oyasu M, et al. POS1062 therapeutic potential of imvotamab, a CD20-targeted bispecific IGM T cell engager, for the treatment of refractory autoimmune disease patients. Ann Rheum Dis. 2024;83:935.
69. Quigley M, Michaelson J, Jones J, et al. CLN-978, a CD19-directed T cell engager (TCE), leads to rapid and deep B cell depletion and has broad potential for development in autoimmune diseases; 2024. Available from: https://acrabstracts.org/abstract/cln-978-a-cd19-directed-t-cell-engager-tce-leads-to-rapid-and-deep-b-cell-depletion-and-has-broad-potential-for-development-in-autoimmune-diseases/ [Last accessed on 26 Feb 2026].
70. Alexander T, Krönke J, Cheng Q, Keller U, Krönke G. Teclistamab-induced remission in refractory systemic lupus erythematosus. N Engl J Med. 2024;391:864-6.
71. Askanase A, Berkani O, Navarra S, et al. Efficacy and safety of cenerimod in patients with moderate to severe systemic lupus erythematosus (SLE): a multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-finding phase 2b trial; 2022. Available from: https://acrabstracts.org/abstract/efficacy-and-safety-of-cenerimod-in-patients-with-moderate-to-severe-systemic-lupus-erythematosus-sle-a-multicenter-randomized-parallel-group-double-blind-placebo-controlled-dose-finding-phase/ [Last accessed on 26 Feb 2026].
72. Zhang SJ, Xu RY, Kang LL. Biomarkers for systemic lupus erythematosus: a scoping review. Immun Inflamm Dis. 2024;12:e70022.
73. Connelly K, Eades LE, Koelmeyer R, et al. Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce. Nat Rev Rheumatol. 2023;19:592-602.
